Skip to main content

Table 1 Demographics of the study subjects who were treated with intravenous combretastatin A-4 phosphate and characteristics of study and fellow eyes at baseline

From: Vascular disrupting agent for neovascular age related macular degeneration: a pilot study of the safety and efficacy of intravenous combretastatin a-4 phosphate

Patient Age Gender Race Previous treatment CNV SE CNV FE BCVA FTH
SE FE SE FE
1 81 F White PDT × 3 Subfoveal occult Disciform Scar* 60 25 187 127
2 82 F Hispanic PDT × 2 Subfoveal occult Subfoveal occult disciform scar* 73 4 204 573
3 84 F White PDT × 2 Subfoveal occult No CNV 64 80 404 183
4 57 M White PDT × 3 Subfoveal minimally classic Extrafoveal active occult foveal disciform scar * 67 73 346 236
5 64 F White PDT × 4 Subfoveal occult with disciform scar Disciform scar 30 PL 519 x
6 70 M White PDT × 2 Subfoveal minimally Subfoveal occult* 72 47 366 256
7 75 F White PDT × 2 Subfoveal occult No CNV 25 72 292 238
8 79 F White PDT × 3 Subfoveal occult Subfoveal occult* 64 48 450 393
Mean (±SD) 74 (±9.6)       56.9 (18.7±) 49.9 (±27.9) 346.0 (±115.2) 286.6(±150.2)
  1. The asterisks indicate the fellow eyes that had active CNV at baseline. CNV = Choroidal neovascular membrane; SE = Study Eye; FE = Fellow Eye, BCVA = Best corrected visual acuity; FTH = central foveal thickness; PDT = photodynamic therapy; M = Male; F = Female; SD = Standard deviation.